Q32 Bio (QTTB) Net Cash Flow Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 453.08% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -125.22% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.46% |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 119.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.66% |
| Dec 31, 2025 | 93.32% |
| Sep 30, 2025 | 32.51% |
| Jun 30, 2025 | 40.32% |
| Mar 31, 2025 | -114.70% |
| Dec 31, 2024 | -4.46% |
| Sep 30, 2024 | -152.98% |
| Jun 30, 2024 | -57.24% |
| Mar 31, 2024 | 779.90% |
| Dec 31, 2023 | -15.94% |
| Sep 30, 2023 | 112.18% |
| Jun 30, 2023 | 84.28% |
| Mar 31, 2023 | -109.04% |
| Dec 31, 2022 | -169.35% |
| Sep 30, 2022 | -549.41% |
| Jun 30, 2022 | -707.00% |
| Mar 31, 2022 | 222.17% |
| Dec 31, 2021 | -66.44% |
| Sep 30, 2021 | -297.59% |
| Jun 30, 2021 | -50.97% |
| Mar 31, 2021 | -226.14% |
| Dec 31, 2020 | 265.77% |
| Sep 30, 2020 | 127.28% |
| Jun 30, 2020 | -67.53% |
| Mar 31, 2020 | 4,124.33% |
| Dec 31, 2019 | -1,199.12% |
| Sep 30, 2019 | 35.50% |
| Jun 30, 2019 | 53.24% |
| Mar 31, 2019 | 139.56% |
| Dec 31, 2018 | 104.68% |
| Sep 30, 2018 | -176.19% |
| Jun 30, 2018 | 903.57% |
| Mar 31, 2018 | -135.50% |